P/B
6,2
Teva Pharmaceutical Industries
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
$47.9B
Market Cap • 10/9/2026
1944
(82 years)
Founded
NYSE
Listing Exchange
Israel
Country
Valuation
P/S
2,8
P/EBITDA
18,5
P/OCF
25,3
P/FCF
35,6
P/E
68,5
BVPS
6,6
EPS
0,6
Market Cap
Market Cap
47,9B
EV
61,2B
EV/Revenue
3,5
EV/EBITDA
23,6
EV/EBIT
38,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Dividend Yield 5Y
0%
Payout
0%
Retained Earnings
-14B
Profitability
Gross Margin
52,5%
EBITDA Margin
15%
EBIT Margin
9,3%
Net Margin
4%
D&A/EBITDA
0%
R&D/Revenue
9,9%
Capex/Revenue
3,2%
Capex/D&A
55,6%
Capex/OCF
29%
SBC/OCF
8,9%
% PPE
10,7%
% Goodwill
39,7%
ROE
9,5%
ROIC
5,4%
Growth
CAGR Revenue 5Y
1,2%
CAGR OCF 5Y
33,3%
Leverage
N.D./EBITDA
5,1
Debt/Equity
0%
Current Ratio
0,9
Quick Ratio
0,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!